Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Conditions
Interventions
LBR-101 High Dose
LBR-101 Low Dose
+1 more
Locations
57
United States
Teva Investigational Site 145
Gilbert, Arizona, United States
Teva Investigational Site 130
Phoenix, Arizona, United States
Teva Investigational Site 117
Scottsdale, Arizona, United States
Teva Investigational Site 161
Anaheim, California, United States
Teva Investigational Site 116
Fullerton, California, United States
Teva Investigational Site 119
Long Beach, California, United States
Start Date
January 31, 2014
Primary Completion Date
February 28, 2015
Completion Date
March 31, 2015
Last Updated
December 9, 2021
NCT07018713
NCT04715685
NCT06810505
NCT06554886
NCT05337033
NCT03404336
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions